{"id":"W4404799352","doi":"10.1002/art.43066","title":"Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial","year":2024,"lang":"en","type":"article","venue":"Arthritis & Rheumatology","topic":"Inflammatory Myopathies and Dermatomyositis","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"EMD Serono; National Institutes of Health; Argenx; Regeneron Pharmaceuticals; Genentech; AstraZeneca; Pfizer; Bristol-Myers Squibb; CSL Behring; Bristol-Myers Squibb Canada; U.S. Department of Defense","keywords":"Abatacept; Medicine; Placebo; Internal medicine; Clinical endpoint; Clinical trial; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004452436,0.001694046,0.004864166,0.0006914285,0.0007929277,0.001583929,0.001542961,0.002735614,0.006365971],"category_scores_gemma":[0.003121568,0.0008128347,0.003160191,0.0008092695,0.001657604,0.001339679,0.0004383708,0.003048791,0.001037119],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001159387,"about_ca_system_score_gemma":0.002266032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008987383,"about_ca_topic_score_gemma":0.001847343,"domain_scores_codex":[0.9978924,0.001159728,0.0001692885,0.0003375749,0.0002228053,0.000218208],"domain_scores_gemma":[0.9976661,0.0006533422,0.0007011745,0.0002223038,0.0002125814,0.0005445453],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9831188,0.004833753,0.0004095529,0.0006280179,0.0007357476,0.00002319163,0.00002649677,0.0001415583,0.00135615,0.00003838246,0.0003396882,0.008348563],"study_design_scores_gemma":[0.9716213,0.0269253,0.000725036,0.00002859551,0.0002011518,0.00001693033,0.000005791132,0.0001660327,0.0001291428,0.00003459974,0.0001400617,0.000005980166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9695765,0.00991546,0.001762768,0.0009582247,0.0007724893,0.01238428,0.001845577,0.0003658504,0.002418869],"genre_scores_gemma":[0.9703,0.004003759,0.003960983,0.001758215,0.001094981,0.0156511,0.001448973,0.00004959021,0.001732321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006365971,"threshold_uncertainty_score":0.02354699,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008470955376790108,"score_gpt":0.2816912617484088,"score_spread":0.2732203063716187,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}